In a first, Lilly's ready-to-use rescue hypoglycemia powder wins US approval
Days after Lilly’s chief of biomedicines Christi Shaw bid farewell to head up Novartis’ $NVS Kite business, the US drugmaker unveiled a fresh approval: a severe hypoglycemia treatment — the first such therapy given the nod in the United States that can be administered without an injection.
Severe hypoglycemia — rapidly falling blood sugar levels that lead to symptoms such as confusion or syncope — typically occurs in diabetics using insulin treatment.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
